Satralizumab, CAS 1535963-91-7

Product Description: Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research[1][2].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Heydari AH, et al. Satralizumab, Novel Interleukine-6 Inhibitor for Preventing Descending Thoracic Aorta Aneurysm Development. Cardiovasc Drugs Ther. 2021 Nov 26. /[2]Duchow A, et al. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegener Dis Manag. 2021 Feb;11(1):49-59.

CAS Number: 1535963-91-7

Molecular Weight: N/A

Compound Purity: 99.82

Research Area: Cancer; Inflammation/Immunology

Solubility: H2O

Target: Interleukin Related

• Artikelnummer: MEXHY-P99112-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99112-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK